Literature DB >> 3622948

Studies on the gastroprotective and ulcer-healing effects of colloidal bismuth subcitrate.

S J Konturek, T Radecki, I Piastucki, D Drozdowicz.   

Abstract

We investigated the gastroprotective effects of colloidal bismuth subcitrate (CBS, De-Nol) in comparison with agents such as sucralfate and methylated PGE2. Both CBS and sucralfate given orally prevented dose dependently the formation of gastric lesions by acidified aspirin, ethanol and restraint stress, CBS being more potent on a weight-to-weight basis than sucralfate. CBS and sucralfate were also equally effective in enhancing the healing rate of chronic gastric and duodenal ulcer induced by serosal application of acetic acid, while methylated PGE2 was completely ineffective in this model. Non-colloidal bismuth subnitrate, in contrast to CBS, was ineffective against stress-induced lesions. CBS stimulated mucosal generation and luminal release of PGE2 dose dependently.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3622948     DOI: 10.1159/000199553

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  15 in total

Review 1.  Role of Helicobacter pylori in duodenal ulcer.

Authors:  E A Rauws
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

2.  Effect of repeated colloidal bismuth subcitrate treatment on the response of the rat gastric mucosa to the presence of luminal ethanol.

Authors:  S M Hinsull; D Bellamy
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

3.  Acute thrombocytopenia after De-Nol.

Authors:  I J Beckingham; G Baird; P J Kesteven
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

4.  Mechanism of action of nonantisecretory agents.

Authors:  J De Wal
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

5.  Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori.

Authors:  T Rokkas; C Pursey; E Uzoechina; L Dorrington; N A Simmons; M I Filipe; G E Sladen
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

Review 6.  Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

Authors:  A J Wagstaff; P Benfield; J P Monk
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

7.  Eicosanoid synthesis in duodenal ulcer disease: decrease in leukotriene C4 by colloidal bismuth subcitrate.

Authors:  A Ahmed; P R Salmon; C R Cairns; M Hobsley; J R Hoult
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

8.  Chemical structure of bismuth compounds determines their gastric ulcer healing efficacy and anti-Helicobacter pylori activity.

Authors:  G S Sandha; R LeBlanc; S J Van Zanten; T D Sitland; L Agocs; N Burford; L Best; D Mahoney; P Hoffman; D J Leddin
Journal:  Dig Dis Sci       Date:  1998-12       Impact factor: 3.199

9.  Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus.

Authors:  D J Muñoz; C Tasman-Jones; J Pybus
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

10.  Inability of cytoprotection to occur during a period of gastric ischemia.

Authors:  G M Frydman; A G Penney; C Malcontenti; P E O'Brien
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.